Public Release: 

Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens

Research presented at 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

European Society of Clinical Microbiology and Infectious Diseases

Madrid, Spain: The antibiotic combination treatment piperacillin-tazobactam was significantly less effective than meropenem when treating potentially fatal bloodstream infections (BSI) caused by ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae and should be avoided when treating these organisms, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) [1].

Researchers from the Centre of Clinical Research at the University of Queensland determined whether piperacillin-tazobactam, a penicillin-based combination therapy, was as effective for treating BSI as the commonly used antibiotic meropenem. Their hypothesis was that definitive therapy with piperacillin-tazobactam was non-inferior to meropenem.

While there was no difference between the two groups regarding subsequent infections of drug-resistant bacteria or C. difficile, the difference in mortality rate was significant. Twenty-three patients, or 12.3%, treated with piperacillin-tazobactam died by the 30-day mark compared with seven patients, or 3.7%, who had been treated with meropenem.

"The use of piperacillin-tatobactam as definitive therapy for bloodstream infections caused by E. coli or K. pneumoniae with non-susceptibility to third-generation cephalosporins was inferior to meropenem and should be avoided in this context," presenting author Dr Patrick Harris concluded in his presentation.

During the last 10 years the rate of carbapenem resistance has been increasing exponentially worldwide. Researchers urgently need reliable data from well-designed trials to guide clinicians in the treatment of antibiotic resistant Gram-negative infections. Physicians face a situation where meropenem, which is commonly used for bloodstream infection, is suspected of driving resistance to carbapenem, a highly effective antibiotic agent that is usually reserved for known or suspected difficult-to-treat multidrug-resistant (MDR) bacterial infections.

Bloodstream infections carry a high risk for morbidity and mortality. Such infections are common in the hospital setting and they often are difficult to treat because K. pneumoniae and E. coli, the leading cause of BSIs, have developed resistance to cephalosporins, a class of antibiotics originally made from fungi.

The team enrolled adult patients from 32 sites in nine countries - most patients were recruited in Singapore, Australia and Turkey. The study included 378 patients between February 2014 and July 2017. Healthcare-associated infections were the most common, accounting for more than half of the infections in the study group. Most infections, 60.9%, originated in the urinary tract before spreading to the bloodstream. And 86.5% of the cases were caused by the E. coli bacteria.

Harris's team examined the primary outcome for these patients, which was mortality at 30 days after the randomisation. Randomisation occurred within 72 hours of the initial blood culture.

The team also noted secondary outcomes, those consisted of the number of days for each patient to reach the resolution of the infection, the clinical and microbiological success at day four, any relapse of the bloodstream infection or a secondary infection with an organism that was resistant to the trial drugs or Clostridium difficile, which is another type of bacteria that may lead to life-threatening symptoms and is sometimes a side effect of antibiotic treatment.

###

Abstract no: O1121, The MERINO Trial: piperacillin-tazobactam versus meropenem for the definitive treatment of bloodstream infections caused by third-generation cephalosporin non-susceptible Escherichia coli or Klebsiella spp.: an international multi-centre open-label non-inferiority randomised controlled trial; session Late breaker: Clinical trials, 16:00 - 18:00, Sunday, 22 April 2018, Hall Q

[1] The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). This year it will take place from 21 - 24 April 2018 in Madrid, Spain. At the world's largest congress combining the fields of infectious diseases and clinical microbiology, researchers will present more than 3,000 regular and late-breaking abstracts with the latest findings and recommendations, which are set to help improve diagnosis, prevention and treatment of infection-related diseases. The congress offers almost 200 sessions, including keynote lectures, symposia, oral sessions, educational workshops and meet-the-expert session. ECCMID expects approximately 13,000 participants from more than 100 countries.

About ESCMID

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is a non-profit organization dedicated to improving the diagnosis, treatment and prevention of infectious diseases in Europe and beyond. The society promotes and supports research, education, training and good medical practice in infection-related disciplines with a special focus on antimicrobial resistance to build capacity throughout the world. http://www.escmid.org

Contact

Chantal Britt
ESCMID Communications Manager
ESCMID Executive Office
P.O. Box 214, CH-4010 Basel
Phone +41 61 508 01 57
Mobile +41 76 588 08 24
Email chantal.britt@escmid.org
http://www.escmid.org

Tara Giroud
ECCMID Communications Assistant
Mobile +41 78 705 79 85
Email taragiroud@gmail.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.